Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (36)

« Back to Publications

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: an economic evaluation based on data from the LENS trial

PREISS D. et al, (2025), Diabetic Medicine

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Judge PK. et al, (2025), Nephrol Dial Transplant, 40, 1175 - 1186

Experience of Linking to the NHS Diabetic Eye Screening Programme Records in the ASCEND-Eye Randomized Trial and Recommendations for Improvement

SAMMONS E., (2025), Contemporary Clinical Trials Communications

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

The Effects of Aspirin and Omega-3 Fatty Acids on Age-Related Macular Degeneration in ASCEND-Eye, A Randomised Placebo Controlled Trial in a Population with Diabetes

SAMMONS E., (2025), BMJ Open

Effects of Aspirin and Omega-3 Fatty Acids on Composite and Subdomain Scores from the NEI-VFQ-25 Questionnaire: The ASCEND-Eye Randomized Controlled Trial

SAMMONS E. et al, (2024), BMC Ophthalmology

ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL

Judge P. et al, (2024), Nephrology Dialysis Transplantation

Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

Mayne K. et al, (2024), Nephrology Dialysis Transplantation

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM evidence, EVIDoa2400179 - EVIDoa2400179

Effects of Aspirin and Omega-3 Fatty Acids on Composite and Subdomain Scores from the NEI-VFQ-25 Questionnaire: The ASCEND-Eye Randomized Controlled Trial

Sammons EL. et al, (2024)

Design, recruitment, and baseline characteristics of the LENS trial

PREISS D. et al, (2024), Diabetic Medicine

ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy

SAMMONS E., (2024), Ophthalmology

ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy

SAMMONS E. et al, (2023), Ophthalmology

Load More